ATIM-17. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) COMBINED WITH NIVOLUMAB (NIVO), IPILIMUMAB (IPI) AND BEVACIZUMAB (BEV) IN PATIENTS (PTS) WITH RECURRENT HIGH GRADE GLIOMAS

BACKGROUND: There is strong pre-clinical evidence that combining CTLA4 and PD-1/PDL-1 blockade with antiangiogenic agents and HFSRT independently enhance anti-tumor immune responses and tumor regression. METHODS: This phase I study includes a safety cohort of 6 pts followed by dose expansion cohort...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Sahebjam, Solmaz, Forsyth, Peter, Tran, Nam, Etame, Arnold, Arrington, John, Jaglal, Michael, Mokhtari, Sepideh, MacAulay, Robert, Wicklund, Melissa, Evernden, Brittany, Gatewood, Tyra, Robinson, Timothy, Raval, Raju, Yu, Michael
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2019
Sujets:
Adult Clinical Trials–Immunologic
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847102/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.017
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires